Journal of Thoracic Oncology最新文献_第10页

60P: The FIN-EGFR study: A retrospective observational study to investigate the treatment landscape and outcomes of early and advanced stage patients with EGFR mutated non-small cell lung cancer (NSCLC) 60P: FIN-EGFR研究：一项回顾性观察性研究，探讨EGFR突变的早期和晚期非小细胞肺癌（NSCLC）患者的治疗前景和结果。

IF 21 1区医学

Journal of Thoracic Oncology Pub Date : 2025-03-01 DOI: 10.1016/S1556-0864(25)00255-2

A. Knuuttila , L. Nurmi , M. Ekblom , A. Bonin , E.K. Heikkila , M. Silvoniemi

引用次数: 0

76P: Long-term survival outcomes with first-line (1L) osimertinib monotherapy and subsequent treatment (tx) patterns: Final analysis of a real-world (rw) study in US patients (pts) with epidermal growth factor receptor-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC) 76P：一线（1L）奥西替尼单药治疗和后续治疗（tx）模式的长期生存结局：对美国表皮生长因子受体突变（EGFRm）晚期非小细胞肺癌（NSCLC）患者（pts）的真实世界（rw）研究的最终分析

IF 21 1区医学

Journal of Thoracic Oncology Pub Date : 2025-03-01 DOI: 10.1016/S1556-0864(25)00271-0

F. Griesinger , X. Wang , P.S. Karia , M. Cooper , L. Servidio , E. Jedy-Agba , J.J. Nieva , D.B. Doroshow

引用次数: 0

6MO: Safety and clinical activity of daraxonrasib (RMC-6236) in RAS mutant non-small cell lung cancer (NSCLC) daraxonrasib （rmmc -6236）治疗RAS突变型非小细胞肺癌（NSCLC）的安全性和临床活性

IF 21 1区医学

Journal of Thoracic Oncology Pub Date : 2025-03-01 DOI: 10.1016/S1556-0864(25)00201-1

S.R. Punekar , D.S. Hong , J. Luo , S-H.I. Ou , M.L. Johnson , A. Spira , I. Garrido-Laguna , J.W. Goldman , B. Herzberg , A. Saltos , P. Mitra , A. Hegde , R. Vora , M. Hiremath , K.C. Arbour

引用次数: 0

24P: 5-year real-world outcomes with first-line (1L) pembrolizumab plus (+) chemotherapy in advanced/metastatic NSCLC 24P：一线（1L）派姆单抗+(+)化疗治疗晚期/转移性NSCLC的5年真实预后

IF 21 1区医学

Journal of Thoracic Oncology Pub Date : 2025-03-01 DOI: 10.1016/S1556-0864(25)00219-9

V. Velcheti , R. Babel , Y-H. Kao , D.R. Chirovsky , A. Namakydoust , S.V. Liu

引用次数: 0

59P: Evaluating the effectiveness of amivantamab plus lazertinib in CHRYSALIS-2 vs EGFR TKI monotherapy in a matched real-world cohort of participants with atypical EGFR-mutated advanced NSCLC 59P：在非典型EGFR突变晚期NSCLC患者的匹配现实世界队列中，评估amivantamab + lazertinib在CHRYSALIS-2与EGFR TKI单药治疗中的有效性

IF 21 1区医学

Journal of Thoracic Oncology Pub Date : 2025-03-01 DOI: 10.1016/S1556-0864(25)00254-0

P. Tomasini , Y. Wang , S-H. Lee , J. Cui , E. Felip , A. Spira , Y. Li , L. Wu , S. Michels , E. Ichihara , J. Neal , L. Demirdjian , C.S. Meyer , Y. Zhang , H. Kanakamedala , A. Louder , L. Trani , I. Leconte , M. Baig , B.C. Cho

引用次数: 0

International Association for the Study of Lung Cancer (IASLC) 国际肺癌研究协会（IASLC）

IF 21 1区医学

Journal of Thoracic Oncology Pub Date : 2025-03-01 DOI: 10.1016/S1556-0864(25)00188-1

引用次数: 0

35P: Clinical and safety outcomes of cancer vaccines in patients with advanced non-small cell lung cancer after first-line therapy: A systematic review and meta-analysis 35P：癌症疫苗在晚期非小细胞肺癌患者一线治疗后的临床和安全性结局：系统回顾和荟萃分析

IF 21 1区医学

Journal of Thoracic Oncology Pub Date : 2025-03-01 DOI: 10.1016/S1556-0864(25)00230-8

S. Chen , P. Wang , Z. Sun , Y. Li , F. Yang , K. Chen , J. Wang , M. Qiu

引用次数: 0

44P: First-line chemo-immunotherapy prognostic factors predicting non-small cell lung cancer (NSCLC) overall survival: Multicentric observational study 44P：一线化疗免疫治疗预测非小细胞肺癌（NSCLC）总生存的预后因素：多中心观察性研究

IF 21 1区医学

Journal of Thoracic Oncology Pub Date : 2025-03-01 DOI: 10.1016/S1556-0864(25)00239-4

R. Ronga , F. Vitiello , F. Ambrosio , B. Miranda , F.J. Romano , G. Viscardi , S. Campione , G. Guggino , A. Vaia , A. Farinaro , P. Maione , C. Gridelli , F. Riccardi

引用次数: 0

Artificial Intelligence Technologies for Managing High-Risk Patients With Immune-Related Adverse Events and Optimizing Timing 人工智能技术用于管理高危患者免疫相关不良事件和优化时机

IF 21 1区医学

Journal of Thoracic Oncology Pub Date : 2025-03-01 DOI: 10.1016/j.jtho.2024.08.004

Fangjie Liu MD, Hui Li MD

引用次数: 0

Predicted Effect of Incidental Pulmonary Nodule Findings on NSCLC Mortality 偶然发现肺结节对非小细胞肺癌死亡率的预测影响。

IF 21 1区医学

Journal of Thoracic Oncology Pub Date : 2025-03-01 DOI: 10.1016/j.jtho.2024.11.009

S. Tuminello PhD , R. Flores MD , M. Untalan MPH , T. Ivic-Pavlicic MPH , C.I. Henschke MD , R. Yip PhD , D.F. Yankelevitz MD , Emanuela Taioli MD, PhD

{"title":"Predicted Effect of Incidental Pulmonary Nodule Findings on NSCLC Mortality","authors":"S. Tuminello PhD , R. Flores MD , M. Untalan MPH , T. Ivic-Pavlicic MPH , C.I. Henschke MD , R. Yip PhD , D.F. Yankelevitz MD , Emanuela Taioli MD, PhD","doi":"10.1016/j.jtho.2024.11.009","DOIUrl":"10.1016/j.jtho.2024.11.009","url":null,"abstract":"<div><h3>Introduction</h3><div>Despite the reduction in mortality by low-dose computed tomography lung cancer screening, the uptake is still low. Patients undergo chest imaging for several other medical reasons, and this is a unique opportunity to detect lung nodules.</div></div><div><h3>Methods</h3><div>In a cohort of patients with NSCLC from the Surveillance, Epidemiology, and End Results-Medicare–linked data, tumor size at previous imaging was calculated as follows: volume doubling time = [(T<sub>2</sub>-T<sub>1</sub>)·ln2]/ln(V<sub>2</sub>/V<sub>1</sub>), solving for the diameter of V<sub>1</sub>. V<sub>1</sub> and V<sub>2</sub> are tumor volume at times T<sub>1</sub> (previous imaging) and T<sub>2</sub> (diagnostic procedure) according to three different growth models. The 10-year lung cancer-specific mortality was calculated as follows: lung cancer survival rate = (−0.0098 × maximum tumor diameter) + 1.</div></div><div><h3>Results</h3><div>A total of 1007 patients who had a chest imaging performed up to 1 year before lung cancer diagnosis were included in this study. The median size of the tumor at diagnosis was 25 mm, and the predicted median tumor size at previous imaging was 12.16 mm, 17.3 mm, and 20.42 mm under the fast, medium, and slow growth model, respectively. Under the fast growth model, a detection of the nodule at previous imaging would have yield a decrease in mortality of 7.79%; the corresponding value for the medium growth model is 4.5% and for the slow growth model 2.45%.</div></div><div><h3>Conclusions</h3><div>Identifying malignant lung nodules in imaging performed for other clinical reasons can help decrease the burden of NSCLC, especially for patients not eligible for low-dose computed tomography and the medically vulnerable. We reveal here that clinical benefits, especially among patients with aggressive disease, can be considerable.</div></div>","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"20 3","pages":"Pages 273-284"},"PeriodicalIF":21.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142621845","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0